Jason Gerberry
BofA Securities, Research Division

We are introducing Axsome, our next company presenter. We've got Mark Jacobson, Chief Operating Officer; and Nick Pizzie, Chief Financial Officer. So gentlemen, first off, thanks for joining us.

Mark Jacobson
Chief Operating Officer

Good morning, everyone, and thanks for having us, Jason. It's good to be here. Obviously, a pretty exciting time for us. So it's nice to be able to chat with you.

Jason Gerberry
BofA Securities, Research Division

So a lot going on at Axsome, recently a high-profile new indication approval for Auvelity and the company has been, I guess, emboldened to convey even a more bullish outlook for the franchise in aggregate. Maybe we could start there.

Just if you can talk about the approval, what was the biggest positive takeaways in terms of product labeling, how that will confer competitiveness for Auvelity, both in its newly indicated disease state as well as the legacy MDD indication.

Mark Jacobson
Chief Operating Officer

Sure. We'd be happy to. And it's coming from a place of just what the current state of the business tells us as opposed to being feeling extra bold or bullish. It's just the state of the business, and we can talk about that.

But to your point, starting with the label, this -- the label now for AD agitation, it's incredibly clean and speaks to the underlying product profile, and that gives the team a lot of ability to educate potential prescribers for both indications.

So that ties to the need in Alzheimer's disease